07 Jan 2001

SUBUTEX 0,4 (SUBUTEX 0,4 mg/-2 mg/-8 mg Sublingualtabletten) - Deutschland

Updated: 07 Jan 2001

SUBUTEX 0,4 mg | -2 mg | -8 mg

Substitutionstherapie bei Opioidabhängigkeit im Rahmen medizinischer, sozialer u. psychotherapeutischer Maßnahmen. Insbes. für die erste Substitutionstherapie von Opioid-Abhängigen mit kürzerer Dauer der Suchterkrankung u. weniger verfestigten Suchterkrankungen. Zur Beh. von Erw. über 18 J. die einer Suchtbehandl. zugestimmt haben.

SUBUTEX 0,4 Description, Presentation and Dosage

SUBUTEX 0,4 Description

SUBUTEX 0,4 Drug Class Description

Einzelstoffe

SUBUTEX 0,4 Drug Description

1 Sublingualtbl. enth.: Buprenorphin-HCl 0,432 mg/2,16 mg/8,64 mg (entspr. 0,4 mg/2 mg/8 mg Buprenorphin).

SUBUTEX 0,4 Generic Name

SUBUTEX 0,4 mg/-2 mg/-8 mg Sublingualtabletten

SUBUTEX 0,4 Presentation

SUBUTEX 0,4 Presentation

SUBUTEX 0,4 mg/-2 mg/-8 mg

SUBUTEX 0,4 Manufacturer

Essex Pharma

Related Learning Zones

CSU Knowledge Centre and CME

CSU Knowledge Centre and CME

This Knowledge Centre is intended for allergists, immunologists, dermatologists and other healthcare professionals involved in the treatment and management of Chronic Spontaneous Urticaria (CSU). In the Knowledge Centre, you will find a disease overview, symposium highlights platform, video channel and additional resources including an events calendar and useful external links. This resource has been given a whole new look and feel, intended to improve accessibility and visual appeal. Recent content additions include a frequently asked questions section, case studies from urticaria experts Professor Christian Vestergaard and Professor Torsten Zuberbier and information on the TARGET My Hives app.

LAL-D Knowledge Centre

LAL-D Knowledge Centre

The Lysosomal Acid Lipase (LAL) Deficiency Knowledge Centre contains a range of accurate, informative clinical content for healthcare professionals. The disease awareness section presents epidemiology, pathophysiology and diagnosis information, among others. The treatment section details the drug characteristics, safety and efficacy of sebelipase alfa – the first and only licenced treatment for LAL deficiency. The resources section contains further clinical content including a video channel presenting expert opinions on diagnostic approach and current prognosis.

Developed by EPG Health Media (Europe) Ltd for epgonline.org, in collaboration and with content provided by Alexion Pharma GmbH

SUBUTEX 0,4 Dosage

SUBUTEX 0,4 Adult Dosage

Lactose 1H2O, Mannitol, Maisstärke, Povidon K 30, Citronensäure, Natriumcitrat, Magnesiumstearat.

SUBUTEX 0,4 Precautions, Reactions and Contraindications

SUBUTEX 0,4 Special Precautions

SUBUTEX 0,4 Special Precautions

Schwere respiratorische Insuffizienz, schwere Leberinsuffizienz, akuter Alkoholismus od. Delirium tremens, Behandl. mit Monoaminooxidasehemmern. Kdr. u. Jugendl. unter 18 J. (keine Erkenntnisse zu Wirksamkeit u. Unbedenklichkeit).

SUBUTEX 0,4 Adverse Reactions

SUBUTEX 0,4 Adverse Reactions

A 85 b, c

Related Drugs - Pain Management

Back to top